Fractyl Health, Inc.

Equities

GUTS

US35168W1036

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:02:10 2024-05-28 pm EDT			5-day change	1st Jan Change
6.655 ^USD	-10.79%		-9.07%	0.00%

May. 20	Fractyl Health, Inc. Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva At Digestive Disease Week 2024	CI
May. 13	Earnings Flash (GUTS) FRACTYL HEALTH Reports Q1 Revenue $33,000	MT

Fractyl Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 13, 2024 at 04:00 pm EDT

Fractyl Health, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 0.033 million compared to USD 0.005 million a year ago. Net loss was USD 3.32 million compared to USD 11.93 million a year ago.

Latest news about Fractyl Health, Inc.

Fractyl Health, Inc. Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva At Digestive Disease Week 2024	May. 20	CI
Earnings Flash (GUTS) FRACTYL HEALTH Reports Q1 Revenue $33,000	May. 13	MT
Fractyl Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Fractyl Health Says New Revita Data Show Sustained Weight Loss, Glucose Control in Type 2 Diabetes	May. 13	MT
Fractyl Health Names Adrian Kimber Chief Commercial Officer; Shares Down	Apr. 02	MT
Fractyl Health, Inc. Announces Appointment of Adrian Kimber as Chief Commercial Officer	Apr. 02	CI
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	Apr. 01	MT
Rising Rate Cut Hopes Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Monday	Apr. 01	MT
Top Premarket Decliners	Apr. 01	MT
Fractyl Health Shares Drop After Wider 4Q Loss	Apr. 01	DJ
Earnings Flash (GUTS) FRACTYL HEALTH Posts Q4 Revenue $7,000	Apr. 01	MT
Fractyl Health, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
Fractyl Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Fractyl Health Shares Rise 40% After FDA Approval of IDE for Revita	Apr. 01	DJ
Fractyl Health, Inc. Receives FDA IDE Approval for the Revita®? Remain-1 Pivotal Study of Weight Maintenance in Obesity After Discontinuation of GLP-1 Based Drugs	Apr. 01	CI
Fractyl Health, Inc.(NasdaqGM:GUTS) added to S&P TMI Index	Mar. 17	CI
Fractyl Health Reports 'Promising' Preclinical Findings From Rejuva Platform; Shares Fall	Mar. 12	MT
Fractyl Health Announces New Results from Its Rejuva® Platform Demonstrating Potent and Durable Effects of A Single Dose of A Human Glp-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the Db/Db Mouse Model of Diabetes and Obesity	Mar. 12	CI
Evercore ISI Initiates Fractyl Health at Outperform Rating	Feb. 28	MT
BofA Securities Initiates Fractyl Health at Buy Rating With $26 Price Target	Feb. 27	MT
Morgan Stanley Initiates Fractyl Health at Overweight Rating With $18 Price Target	Feb. 27	MT
Fractyl Health Appoints Samuel Conaway to its Board of Directors	Feb. 20	CI
Fractyl Health Insider Bought Shares Worth $4,999,995, According to a Recent SEC Filing	Feb. 08	MT
Fractyl Health Insider Bought Shares Worth $6,999,990, According to a Recent SEC Filing	Feb. 08	MT
Fractyl Health, Inc.(NasdaqGM:GUTS) added to NASDAQ Composite Index	Feb. 04	CI

Chart Fractyl Health, Inc.

Duration

Period

More charts

Company Profile

Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity. The Revita DMR System (Revita), the Companyâs lead product candidate, is an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The Revita system is designed to enable durable and repeatable metabolic improvement via hydrothermal ablation of the dysfunctional duodenal mucosa to address duodenal pathology and consequent metabolic disease progression directly. The Company is involved in enrolling is pivotal Revitalize-1 study in patients with inadequately controlled T2D. It is also developing Rejuva, a locally administered, adeno-associated virus (AAV), delivered pancreatic gene therapy (PGTx), platform. Rejuva is designed to enable long-term remission of T2D and obesity.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.46 USD

Average target price

22 USD

Spread / Average Target

+194.91%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FRACTYL HEALTH, INC.	0.00%	357M
VERTEX PHARMACEUTICALS INCORPORATED	+9.86%	118B
REGENERON PHARMACEUTICALS, INC.	+9.93%	106B
BIONTECH SE	-11.18%	23.4B
ARGENX SE	-1.69%	22.1B
GENMAB A/S	-10.23%	18.34B
WUXI APPTEC CO., LTD.	-41.92%	16.59B
BEIGENE, LTD.	-15.59%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.69%	14.03B
SAREPTA THERAPEUTICS, INC.	+16.32%	11.67B

Bio Therapeutic Drugs